Garg Naveen, Muduli Subrat K, Kapoor Aditya, Tewari Satyendra, Kumar Sudeep, Khanna Roopali, Goel Pravin Kumar
Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Indian Heart J. 2017 Jul-Aug;69(4):458-463. doi: 10.1016/j.ihj.2017.01.015. Epub 2017 Jan 31.
The accuracy of various 10-year cardiovascular disease (CVD) risk calculators in Indians may not be the same as in other populations. Present study was conducted to compare the various calculators for CVD risk assessment and statin eligibility according to different guidelines.
Consecutive 1110 patients who presented after their first myocardial infarction were included. Their CVD risk was calculated using Framingham Risk score- Coronary heart disease (FRS-CHD), Framingham Risk Score- Cardiovascular Disease (FRS-CVD), QRISK2, Joint British Society risk calculator 3 (JBS3), American College of Cardiology/American Heart Association (ACC/AHA), atherosclerotic cardiovascular disease (ASCVD) and WHO risk charts, assuming that they had presented one day before cardiac event for risk assessment. Eligibility for statin uses was also looked into using ACC/AHA, NICE and Canadian guidelines.
FRS-CVD risk assessment model has performed the best as it could identify the highest number of patients (51.9%) to be at high CVD risk while WHO and ASCVD calculators have performed the worst (only 16.2% and 28.3% patients respectively were stratified into high CVD risk) considering 20% as cut off for high risk definition. QRISK2, JBS3 and FRS-CHD have performed intermediately. Using NICE, ACC/AHA and Canadian guidelines; 76%, 69% and 44.6% patients respectively were found to be eligible for statin use.
FRS-CVD appears to be the most useful for CVD risk assessment in Indians, but the difference may be because FRS-CVD estimates risk for several additional outcomes as compared with other risk scores. For statin eligibility, however, NICE guideline use is the most appropriate.
各种10年心血管疾病(CVD)风险计算器在印度人中的准确性可能与其他人群不同。本研究旨在根据不同指南比较各种用于CVD风险评估和他汀类药物适用资格的计算器。
纳入1110例首次心肌梗死后前来就诊的连续患者。假设他们在心脏事件前一天前来进行风险评估,使用弗雷明汉风险评分 - 冠心病(FRS-CHD)、弗雷明汉风险评分 - 心血管疾病(FRS-CVD)、QRISK2、英国联合协会风险计算器3(JBS3)、美国心脏病学会/美国心脏协会(ACC/AHA)、动脉粥样硬化性心血管疾病(ASCVD)和世界卫生组织风险图表计算他们的CVD风险。还根据ACC/AHA、英国国家卫生与临床优化研究所(NICE)和加拿大指南研究了他汀类药物使用的适用资格。
FRS-CVD风险评估模型表现最佳,因为它能识别出最多的高CVD风险患者(51.9%),而将20%作为高风险定义的临界值时,世界卫生组织和ASCVD计算器表现最差(分别只有16.2%和28.3%的患者被分层为高CVD风险)。QRISK2、JBS3和FRS-CHD表现中等。根据NICE、ACC/AHA和加拿大指南,分别有76%、69%和44.6%的患者被发现符合使用他汀类药物的条件。
FRS-CVD似乎对印度人的CVD风险评估最有用,但差异可能是因为与其他风险评分相比,FRS-CVD估计了几种额外结局的风险。然而,对于他汀类药物的适用资格,使用NICE指南最为合适。